MadihaNaseemMD

Oncology • Bakersfield, CA

Physician

Join to view full profile

Dr. Naseem is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Naseem's full profile

Already have an account?

Office
2620 Chester Ave
Bakersfield, CA 93301
Phone+1 661-863-2200

Fax+1 661-863-2881

Education & Training

St Mary Medical CenterResidency, Internal Medicine, 2018 - 2021
Los Angeles General Medical CenterPost-Doctoral Fellowship, 2016 - 2018
University of Toronto Faculty of MedicineClass of 2016

Certifications & Licensure

CA State Medical License 2019 - 2025
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

22 citations
Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets.
Alberto Puccini, Kelsey Poorman, Fabio Catalano, Andreas Seeber, Richard M Goldberg
Oncogene. 2022-06-01
8 citations
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients.
Alberto Puccini, Andreas Seeber, Joanne Xiu, Richard M. Goldberg, Davide Soldato
NPJ Precision Oncology. 2021-10-27
3 citations
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients.
Madiha Naseem, Shu Cao, Dongyun Yang, Joshua Millstein, Alberto Puccini
Scientific Reports. 2021-06-09

Lectures

Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFI...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE an...
2019 ASCO Annual Meeting - 6/1/2019